Latest Breaking News On - Silverback therapeutics - Page 5 : vimarsana.com

Effect of Fluvoxamine vs Placebo on Time to Sustained Recovery in Outpatients With Mild to Moderate COVID-19

This randomized, placebo-controlled platform trial compares the use of low-dose fluvoxamine (50 mg twice daily) for 10 days compared with placebo in outpatients

United statesEugene passamaniPardes biosciencesSusanna naggieVanderbilt university medical centerTranslational sciences samuel bozzetteBoehringer ingelheimTranslational sciencesEndpoint healthFaron pharmaceuticalsNational institutes of healthBiomedical advanced researchUs centers for diseaseDuke clinical research instituteDevelopment authorityArrowhead pharmaceuticals

ARS Pharmaceuticals (SPRY) Closes Merger with Silverback Therapeutics (SBTX)

ARS Pharmaceuticals (SPRY) Closes Merger with Silverback Therapeutics (SBTX)
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Peter thompsonBrent saundersPeter kolchinskyPratik shahLaura shawverJonathan leffMichael kellyRichard lowenthalSaqib islamPhillip schneiderRajeev dadooCompany new drug applicationOrbimed advisorsDeerfield institutePharmaceuticals corporationBeauty health company

SHAREHOLDER ALERT: Weiss Law Reminds SBTX, RMED, RCOR, and BTRS Shareholders About Its Ongoing Investigations

/PRNewswire/ If you own shares in any of the companies listed above and would like to discuss our investigations or have any questions concerning this.

New yorkUnited statesJoshua rubinRocket pharmaceuticalsSilverback therapeutics incRocket pharmaceuticals incRenovacor incRa medical systems incCatheter precision incPharmaceuticals incSilverback therapeuticsMedical systemsCatheter precisionRocket pharmaceutical octoberWeiss law

SHAREHOLDER ALERT: Weiss Law Reminds SBTX, RMED, RCOR, and BTRS Shareholders About Its Ongoing Investigations

/PRNewswire/ If you own shares in any of the companies listed above and would like to discuss our investigations or have any questions concerning this.

New yorkUnited statesJoshua rubinRocket pharmaceuticalsSilverback therapeutics incRocket pharmaceuticals incRenovacor incRa medical systems incCatheter precision incPharmaceuticals incSilverback therapeuticsMedical systemsCatheter precisionRocket pharmaceutical october

Silverback Therapeutics, Inc announces the FDA s acceptance of ARS Pharmaceuticals NDA for neffy® (epinephrine nasal spray) for the Treatment of Allergic Reactions (type I) including Anaphylaxis - Silverback Therapeutics (NASDAQ:SBTX) - Press Release

neffy has potential to be the first non-injectable medicine indicated to treat allergic reactions (type I) including anaphylaxis in the U.S., if appro

United statesRichard lowenthalExchange commissionDrug administrationPharmaceuticals incSilverback therapeutics incNew drug applicationPrescription drug user fee actAllergic reactionsSilverback therapeuticsPrivate securities litigation reform actQuarterly reportInvestor relations